Loading…
Intimate Rose was cited for unlawfully selling unapproved and misbranded compounded drug products, specifically semaglutide and tirzepatide formulations, through its website. The company made false or misleading claims that its compounded products contained "the same active ingredient" as FDA-approved drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, violating sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. Because compounded drugs are not FDA-approved, these equivalence claims misrepresented the products' regulatory status and characteristics, resulting in the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FDCA.